Who
Joshua S. Boger
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, CervoMed; CEO, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 1,613
- Buys
- 1
- Sells
- 309
- Bought
- $6.0M
- Sold
- $178.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Feb 2006
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CRVO CervoMedBiotechnology | SEC FORM 4 Bought | $3.0M955,414 at $3.14 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code P | —955,414 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code P | —955,414 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code P | —955,414 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code P | —955,414 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVO CervoMedBiotechnology | SEC FORM 4 Bought | $3.0M955,414 at $3.14 | filing |
| 8 Jun 2026filed 10 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,150 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,150 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,100 at $0.00 | filing |
| 14 Jun 2024filed 14 Jun 2024 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 26 Feb 2024filed 28 Feb 2024 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code X | —495,995 | filing |
| 26 Feb 2024filed 28 Feb 2024 | CRVO CervoMedBiotechnology | SEC FORM 4 Code X | —495,995 | filing |
| 26 Feb 2024filed 28 Feb 2024 | CRVO CervoMedBiotechnology | SEC FORM 4 Sold | —36 | filing |
| 12 Feb 2024filed 13 Feb 2024 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 Jun 2017filed 9 Jun 2017 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,941 | filing |
| 8 Jun 2017filed 9 Jun 2017 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,941 | filing |
| 1 Jun 2017filed 5 Jun 2017 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,188 at $0.00 | filing |
| 1 Jun 2017filed 5 Jun 2017 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —2,941 | filing |
| 1 Jun 2017filed 5 Jun 2017 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,295 at $0.00 | filing |
| 1 Jun 2017filed 5 Jun 2017 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,941 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.